Citi Maintains 'Hold' Rating on Progenics Pharmaceuticals (PGNX), Increases Price Target
More News related to PGNX
- Progenics Announces Progress and Presentations in HIV Therapy Program
- Progenics Initiates Phase 1 Clinical Study of Targeted Therapy for Prostate Cancer
- Progenics Pharma (PGNX) Reports In-Line Q2 Loss of $0.08
- Progenics Pharmaceuticals Reports Second Quarter 2008 Results
- Friedman Billings Downgrades Progenics Pharma (PGNX) to Underperform
More News related to Analyst Comments
- Research and Markets: China's Fast Food Industry is Expected to Grow at a CAGR of around 25% During 2008-2011 According to This Latest Research
- Changes in StatoilHydro's corporate executive committee
- Research and Markets: Ordina Has Recorded Strong Financial Performance in the Recent Five Years the Company's Revenues Increased by 25.5% in 2007, When Compared to Revenues of 2006
- COMPLETExRM's Success Leads to New Funding
- Research and Markets: 2008 Study on the Butanediol Market Outlook Includes Profiles of Major Producers and Brief Overview of the Market for Employed Feedstock - Maleic Anhydride
Citi maintains a 'Hold' rating on Progenics Pharmaceuticals Inc (Nasdaq: PGNX), but increases price target from $13 to $17.
Citi analyst says, "PGNX announced Relistor pricing of $40 per vial, or $280 for the 7 vial pack. Assuming a 20% manufacturer discount to the wholesale price results in a price of $32 per vial. This is considerably above our previous estimate of $25 per vial...While upside to our current Relistor sales estimates is possible, depending on off-label use, we would rather take a conservative approach at this point."
Progenics Pharmaceuticals, Inc. (Progenics) is a biopharmaceutical company focusing on the development and commercialization of therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases.[SM]
Related Categories
Analyst CommentsStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
